JP2019519208A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519208A5 JP2019519208A5 JP2018559329A JP2018559329A JP2019519208A5 JP 2019519208 A5 JP2019519208 A5 JP 2019519208A5 JP 2018559329 A JP2018559329 A JP 2018559329A JP 2018559329 A JP2018559329 A JP 2018559329A JP 2019519208 A5 JP2019519208 A5 JP 2019519208A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- antibody
- cell
- ctla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201603721TA SG10201603721TA (en) | 2016-05-10 | 2016-05-10 | Anti-CTLA-4 Antibodies |
| SG10201603721T | 2016-05-10 | ||
| PCT/EP2017/058956 WO2017194265A1 (en) | 2016-05-10 | 2017-04-13 | Anti-CTLA-4 Antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519208A JP2019519208A (ja) | 2019-07-11 |
| JP2019519208A5 true JP2019519208A5 (https=) | 2019-08-22 |
| JP6650537B2 JP6650537B2 (ja) | 2020-02-19 |
Family
ID=58609383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559329A Active JP6650537B2 (ja) | 2016-05-10 | 2017-04-13 | 抗ｃｔｌａ−４抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11267887B2 (https=) |
| EP (1) | EP3455255B1 (https=) |
| JP (1) | JP6650537B2 (https=) |
| KR (1) | KR20190015715A (https=) |
| CN (1) | CN109563165B (https=) |
| AU (1) | AU2017262448A1 (https=) |
| CA (1) | CA3023787A1 (https=) |
| SG (2) | SG10201603721TA (https=) |
| TW (1) | TW201739763A (https=) |
| WO (1) | WO2017194265A1 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014013138B1 (pt) | 2011-12-01 | 2022-06-28 | Chemocentryx, Inc | Compostos de anilinas substituídas como antagonistas de ccr(4) e composição farmacêutica compreendendo os mesmos |
| EP3711488A1 (en) | 2015-05-06 | 2020-09-23 | Snipr Technologies Limited | Altering microbial populations & modifying microbiota |
| MA53355A (fr) | 2015-05-29 | 2022-03-16 | Agenus Inc | Anticorps anti-ctla-4 et leurs procédés d'utilisation |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| SG10201603721TA (en) * | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| DK3551660T5 (da) | 2016-12-07 | 2024-09-02 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| CA3073984A1 (en) * | 2017-09-21 | 2019-03-28 | Eucure (Beijing) Biopharma Co., Ltd | Anti-ctla4 antibodies and uses thereof |
| EP3707162A1 (en) | 2017-11-10 | 2020-09-16 | Agency for Science, Technology and Research | Il2rbeta/common gamma chain antibodies |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| WO2019157533A1 (en) * | 2018-02-12 | 2019-08-15 | The General Hospital Corporation | Chimeric antigen receptors targeting the tumor microenvironment |
| US10760075B2 (en) * | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| CA3100349A1 (en) * | 2018-05-17 | 2019-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor inhibition by phosphatase recruitment |
| KR102817790B1 (ko) | 2018-08-29 | 2025-06-05 | 케모센트릭스, 인크. | C-c 케모카인 수용체 4(ccr4) 길항제 및 하나 이상의 면역 체크포인트 억제제를 사용한 병용 요법 |
| TW202039557A (zh) | 2018-11-09 | 2020-11-01 | 新加坡商優其洛伊生物私人有限公司 | 介白素2受體β(IL2Rβ)/共同γ鏈抗體 |
| TW202031683A (zh) | 2018-11-09 | 2020-09-01 | 新加坡商優其洛伊生物私人有限公司 | 介白素2受體β(IL2Rβ)/共同γ鏈抗體 |
| KR20210108978A (ko) | 2018-12-21 | 2021-09-03 | 오제 이뮈노테라프틱스 | 이작용성 항-pd-1/il-7 분자 |
| SG11202106764YA (en) * | 2018-12-27 | 2021-07-29 | Gigagen Inc | Anti-ctla-4 binding proteins and methods of use thereof |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| CN110343180B (zh) * | 2019-07-25 | 2021-03-30 | 北京免疫方舟医药科技有限公司 | 抗ctla-4抗体及其应用 |
| WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
| WO2021250594A1 (en) | 2020-06-11 | 2021-12-16 | Nantbio, Inc. | Anti-ctla4 monoclonal antibodies and chimeric antigen receptors |
| KR20230033719A (ko) * | 2020-07-02 | 2023-03-08 | 기가젠, 인코포레이티드 | 항-ctla-4 결합 단백질 및 이의 사용 방법 |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| WO2022169269A1 (ko) * | 2021-02-03 | 2022-08-11 | 주식회사 유틸렉스 | 항 ctla-4 항체 및 이의 용도 |
| RU2757418C1 (ru) * | 2021-03-04 | 2021-10-15 | федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный университет" | Тетрадекапептидный антагонист взаимодействия CTLA-4 c B7-1 |
| MX2023011964A (es) | 2021-04-09 | 2024-01-08 | Ose Immunotherapeutics | Nuevo andamio para moléculas bifuncionales con propiedades mejoradas. |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| JP2025525886A (ja) | 2022-08-02 | 2025-08-07 | オーエスイー・イミュノセラピューティクス | Ｃｄ２８に対する多機能性分子 |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| EP4687991A1 (en) | 2023-03-30 | 2026-02-11 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2025137321A1 (en) * | 2023-12-21 | 2025-06-26 | Fenwal, Inc. | System and method for affinity cell selection |
| EP4599843A1 (en) | 2024-02-09 | 2025-08-13 | Fundació Institut de recerca de l'Hospital de la Santa Creu i Sant Pau | Car and modified cd200r combination |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE311895T1 (de) | 1992-05-26 | 2005-12-15 | Immunex Corp | Neue zytokine die cd30 binden |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| ITRM20010408A1 (it) | 2001-07-10 | 2003-01-10 | Univ Napoli Federico Ii | Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2. |
| IL162835A0 (en) | 2002-01-09 | 2005-11-20 | Medarex Inc | Human monoclonal antibodies against cd30 |
| AU2005235811B2 (en) | 2004-02-06 | 2011-11-03 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
| AU2005259221B2 (en) | 2004-07-01 | 2011-02-10 | Innate Pharma | Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use |
| JP5225069B2 (ja) | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| US8350011B2 (en) | 2006-08-04 | 2013-01-08 | Medimmune Limited | Antibodies to ErbB2 |
| US7994306B2 (en) | 2006-11-13 | 2011-08-09 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Methods of treating cancer using siRNA molecules directed against CD24 |
| KR101598229B1 (ko) | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ3에 대한 항체 및 이의 용도 |
| CL2008003526A1 (es) | 2007-11-30 | 2010-01-11 | Medarex Inc | Conjugado de anticuerpo-molécula asociada que comprende un anticuerpo monoclonal humano anti b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8 humana; composición que lo comprende; método in vitro de inhibición de célula tumoral que expresa b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8; y uso para tratar cancer. |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP2478110B1 (en) | 2009-09-16 | 2016-01-06 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| CA2800488A1 (en) | 2010-05-26 | 2011-12-01 | Regents Of The University Of Minnesota | Single-chain variable fragment anti-cd133 antibodies and uses thereof |
| CA2809089C (en) | 2010-08-23 | 2018-12-18 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| WO2012147713A1 (ja) | 2011-04-25 | 2012-11-01 | 第一三共株式会社 | 抗ｂ７－ｈ３抗体 |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| PH12014500483A1 (en) | 2011-09-30 | 2014-04-14 | Regeneron Pharma | Anti-erbb3 antibodies and uses thereof |
| US9422351B2 (en) | 2011-11-03 | 2016-08-23 | The Trustees Of The University Of Pennsylvania | Isolated B7-H4 specific compositions and methods of use thereof |
| US9381244B2 (en) | 2012-09-07 | 2016-07-05 | King's College London | VISTA modulators for diagnosis and treatment of cancer |
| EP2912063A1 (en) | 2012-10-23 | 2015-09-02 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-ctla-4 antibodies to treat cancer |
| CA2894879A1 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
| US9790282B2 (en) | 2013-03-25 | 2017-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD276 polypeptides, proteins, and chimeric antigen receptors |
| JP6595458B2 (ja) | 2013-09-20 | 2019-10-23 | ブリストル−マイヤーズ スクイブ カンパニー | 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ |
| WO2015097536A2 (en) | 2013-12-24 | 2015-07-02 | Janssen Pharmaceutical Nv | Anti-vista antibodies and fragments |
| CN104974253A (zh) * | 2014-04-01 | 2015-10-14 | 上海中信国健药业股份有限公司 | 抗ctla-4/pd-1双特异性抗体、其制备方法及应用 |
| SG10201603721TA (en) * | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
-
2016
- 2016-05-10 SG SG10201603721TA patent/SG10201603721TA/en unknown
-
2017
- 2017-04-13 KR KR1020187035791A patent/KR20190015715A/ko not_active Ceased
- 2017-04-13 AU AU2017262448A patent/AU2017262448A1/en not_active Abandoned
- 2017-04-13 US US16/099,652 patent/US11267887B2/en active Active
- 2017-04-13 CA CA3023787A patent/CA3023787A1/en not_active Abandoned
- 2017-04-13 US US15/486,468 patent/US9758583B2/en active Active
- 2017-04-13 EP EP17718870.3A patent/EP3455255B1/en active Active
- 2017-04-13 CN CN201780029330.5A patent/CN109563165B/zh active Active
- 2017-04-13 JP JP2018559329A patent/JP6650537B2/ja active Active
- 2017-04-13 TW TW106112375A patent/TW201739763A/zh unknown
- 2017-04-13 WO PCT/EP2017/058956 patent/WO2017194265A1/en not_active Ceased
- 2017-04-13 SG SG11201809857TA patent/SG11201809857TA/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519208A5 (https=) | ||
| JP2018508475A5 (https=) | ||
| US11690908B2 (en) | Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy | |
| AU2021200091B2 (en) | Chimeric antigen receptor compositions | |
| JP2018500924A5 (https=) | ||
| JP2017536111A5 (https=) | ||
| JP2017538441A5 (https=) | ||
| JP2018527912A5 (https=) | ||
| JP2020533960A (ja) | 抗ｉｌ１ｒａｐ抗体 | |
| RU2017116847A (ru) | Антитела к pd-1 | |
| FI3250592T3 (fi) | Transtyretiinin vastaisia vasta-aineita | |
| CN112955179A (zh) | 拮抗性抗肿瘤坏死因子受体超家族多肽 | |
| CA3045508A1 (en) | Methods for modulation of car-t cells | |
| JP2023073965A (ja) | 癌関連免疫抑制阻害剤 | |
| EP4673476A1 (en) | Molecules that bind to b-cell activating factor receptor polypeptides | |
| HK40096809A (zh) | 拮抗性抗肿瘤坏死因子受体超家族抗体 | |
| HK40104763A (zh) | 拮抗性抗肿瘤坏死因子受体超家族抗体 | |
| RU2024115283A (ru) | Композиции vcar и способы применения |